Trial Profile
Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2020
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 16 Nov 2020 Status changed from active, no longer recruiting to completed.
- 23 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
- 04 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.